Overview

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide. For people who need to discontinue treatment, it is unknown whether the weight regain, its accompanied health benefits could be ameliorated with a gradual reduction in semaglutide. The investigators will study if a gradual reduction of semaglutide is associated with different heart risk profile and hormones involved in energy regulation as compared to immediate treatment cessation.

Phase:

PHASE3

Details

Lead Sponsor:

Mount Sinai Hospital, Canada

Collaborator:

Heart and Stroke Foundation of Canada